Clinical Commissioning Policy Statement: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Document first published:
Page updated:
Publication type:

Abatacept is recommended as a treatment option through routine commissioning for patients (adults and children 2 years and over) with severe, treatment resistant morphoea within the criteria set out in this document.